Suppr超能文献

经直肠超声与腹部超声测量前列腺体积的比较及其对前列腺癌诊断中前列腺特异抗原密度测量的意义

[Comparison of prostate volume measured by transrectal and abdominal echography and its implication for the measurement of the PSA density for the diagnosis of prostate cancer].

作者信息

Rodríguez-Patrón Rodríguez Rafael, Mayayo Dehesa Teodoro, Lennie Zucharino Alberto, González Galán Arturo

机构信息

Unidad de Ecografía Urológica y UNED, Madrid, España.

出版信息

Arch Esp Urol. 2002 Sep;55(7):797-806.

Abstract

OBJECTIVE

To compare PSA density (PSAD) results based on prostate volume measurements obtained by either transrectal or abdominal ultrasound (US) in the diagnosis of prostate cancer.

METHODS

We prospectively selected 420 consecutive subjects whom at the time of a transrectal US (TRUS) guided biopsy or an abdominal US had the other US evaluation done within the previous 6 months and who did not undergo hormonal, surgical o radiotherapeutic therapy. For both abdominal and transrectal US PSAD (PSA/volume) were obtained from this data and compared, with volumes calculated using the formula: V = antero-posterior diameter2 x transverse diameter/2.

RESULTS

140 patients had prostate cancer (33.8%). Using Student's t test mean differences were 0.27 cm for anteroposterior diameter, 0.39 cm for transverse diameter, 3.36 cc for volume and 0.014 for PSAD, being the differences significative in all cases (p < 0.001). When ROC curves were calculated for TRUS PSAD and abdominal PSAD areas obtained were 0.66 and 0.67 respectively. For a PSAD cut off point of 0.15, in patients with PSA values between 4-10 ng/ml Sensitivity was 0.77 for TRUS and 0.75 for abdominal US, and specificity was 0.40 and 0.49 respectively.

CONCLUSIONS

Although statistically significative differences were found in all measurements between TRUS and abdominal US, most probably due to the high number of patients, these differences have little clinical relevance as the other results show. In our experience PSAD calculation by abdominal US has the same utility than by transrectal US and avoids its mayor inconvenience which is to perform TRUS.

摘要

目的

比较经直肠或腹部超声(US)测量前列腺体积所得的前列腺特异抗原密度(PSAD)结果在前列腺癌诊断中的应用。

方法

我们前瞻性地连续选取了420名受试者,这些受试者在接受经直肠超声(TRUS)引导下活检或腹部超声检查时,在过去6个月内还接受了另一种超声评估,且未接受激素、手术或放射治疗。从这些数据中获取腹部和经直肠超声的PSAD(前列腺特异抗原/体积)并进行比较,体积使用公式V =前后径²×横径/2计算。

结果

140例患者患有前列腺癌(33.8%)。使用学生t检验,前后径平均差异为0.27厘米,横径为0.39厘米,体积为3.36立方厘米,PSAD为0.014,所有情况下差异均具有统计学意义(p < 0.001)。计算TRUS PSAD和腹部PSAD的ROC曲线时,所得面积分别为0.66和0.67。对于PSAD截断点为0.15,前列腺特异抗原值在4 - 10纳克/毫升之间的患者,TRUS的灵敏度为0.77,腹部超声为0.75,特异性分别为0.40和0.49。

结论

尽管TRUS和腹部超声在所有测量中均发现有统计学意义的差异,很可能是由于患者数量众多,但正如其他结果所示,这些差异几乎没有临床相关性。根据我们的经验,腹部超声计算PSAD与经直肠超声具有相同的效用,且避免了经直肠超声的主要不便之处,即需要进行经直肠超声检查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验